10-Q: Alto Neuroscience Reports Third Quarter 2024 Results; Phase 2b Trial of ALTO-100 in MDD Fails to Meet Primary Endpoint

Alto Neuroscience's third quarter report reveals a net loss of $16.8 million and the failure of its Phase 2b trial of ALTO-100 in MDD to meet its primary endpoint, while highlighting ongoing clinical trials and a new convertible loan agreement.

Summary

• Alto Neuroscience reported a net loss of $16.8 million for the three months ended September 30, 2024, and $46.2 million for the nine months ended September 30, 2024.
• The company's research and development expenses were $13.1 million for the quarter and $36.2 million for the nine-month period.
• General and administrative expenses were $5.8 million for the quarter and $15.4 million for the nine-month period.
• A Phase 2b study of ALTO-100 in patients with MDD did not meet its primary endpoint, but a pre-specified analysis of the adjunctive treatment population showed a clinically meaningful effect.
• The company is continuing its Phase 2b study of ALTO-100 in bipolar depression, with topline data expected in 2026.
• Alto Neuroscience is also progressing with Phase 2b trials for ALTO-300 in MDD, and Phase 2 proof-of-concept trials for ALTO-203 and ALTO-101.
• The company entered into a convertible loan agreement with The Wellcome Trust Limited for up to approximately $11.7 million to advance the development of ALTO-100 in bipolar depression.
• As of September 30, 2024, the company had cash, cash equivalents, and restricted cash of $182.2 million, which is expected to fund operations into 2027.

Sentiment

Score: 4

Explanation: The document presents mixed results, with a significant setback in the ALTO-100 MDD trial offset by progress in other areas and a new funding agreement. The failure of the primary endpoint in the ALTO-100 MDD trial is a major negative, but the company's financial runway and ongoing trials provide some positive aspects. The overall sentiment is cautiously negative due to the trial failure.

Positives

• A pre-specified analysis of the adjunctive treatment population in the ALTO-100 MDD trial showed a clinically meaningful effect, suggesting potential for the drug in specific patient groups.
• The company secured a convertible loan agreement with The Wellcome Trust Limited for up to approximately $11.7 million, providing additional funding for the ALTO-100 bipolar depression study.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations into 2027, providing a stable financial runway.
• The company is progressing with multiple Phase 2 trials for other product candidates, including ALTO-300, ALTO-203, and ALTO-101.

Negatives

• The Phase 2b study of ALTO-100 in MDD failed to meet its primary endpoint, indicating a setback in the development of this product candidate for this indication.
• The company reported a net loss of $16.8 million for the three months ended September 30, 2024, and $46.2 million for the nine months ended September 30, 2024, highlighting ongoing financial losses.
• The company's research and development expenses were $13.1 million for the quarter and $36.2 million for the nine-month period, indicating significant ongoing costs.
• General and administrative expenses were $5.8 million for the quarter and $15.4 million for the nine-month period, reflecting increasing operational costs.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• Clinical trials may be delayed or unsuccessful, and regulatory approvals may not be obtained.
• The company may require substantial additional financing to achieve its goals, and failure to obtain additional capital could cause delays or termination of development efforts.
• The company relies heavily on biomarker data from its Platform, and the FDA may not agree with this approach or the company may be unable to develop necessary companion diagnostics.
• The company faces competition from other biopharmaceutical companies, and its product candidates may not achieve market acceptance.
• The company is dependent on key personnel, and the loss of their services could harm the business.
• The company's intellectual property rights may not be adequately protected, and third parties may infringe on its patents.
• The company is subject to various laws and regulations, and failure to comply could result in penalties.
• The company relies on third-party manufacturers and suppliers, and their failure to perform could disrupt the supply of product candidates.
• The company's stock price may be volatile and fluctuate substantially.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2027. The company expects to report topline data from the ALTO-300 Phase 2b trial in the first half of 2025, ALTO-203 Phase 2 POC trial in the first half of 2025, and ALTO-101 Phase 2 POC trial in the second half of 2025. Topline data from the ALTO-100 bipolar depression trial is expected in 2026.

Management Comments

• The company believes the preliminary analyses in the adjunctive population and in the patients that were confirmed to be compliant with study medication provide strong support for continuing the bipolar depression study with ALTO-100.
• The company believes the preliminary analyses in the adjunctive population and in the patients that were confirmed to be compliant with study medication provide evidence that our enrichment approach has the potential to identify patients that could demonstrate a better response to ALTO-100.

Industry Context

The report highlights the challenges and uncertainties inherent in neuropsychiatric drug development, a field with a high rate of failure. The company's approach of using biomarkers to identify patient populations is novel and unproven, and the company faces competition from other biopharmaceutical companies developing treatments for similar conditions.

Comparison to Industry Standards

• The document notes that drug development in the field of neuropsychiatry and CNS disorders has seen very limited success historically, with a 7.3% and 6.2% likelihood of approval from Phase 1 in psychiatry and neurology, respectively, highlighting the high risk nature of the company's work.
• The company's approach of using biomarkers to identify patient populations is novel and unproven, and does not have significant precedent with the FDA, making it difficult to compare to industry standards.
• The company's reliance on internal clinical development expertise is a deviation from the industry norm of using CROs, making it difficult to compare to industry standards.
• The company's reliance on sole source and limited source suppliers for certain drug substances, drug products, raw materials, samples, components, and other materials used in its product candidates is a common practice in the industry, but also a risk factor.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the mixed results and the failure of the ALTO-100 MDD trial.
• Employees may be affected by the company's financial performance and strategic decisions.
• Patients may benefit from the development of new treatments for neuropsychiatric disorders, but the timeline for availability is uncertain.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• Continue enrollment in the Phase 2b study of ALTO-100 in bipolar depression, with topline data expected in 2026.
• Continue enrollment in the Phase 2b trial of ALTO-300 in MDD, with topline data expected in the first half of 2025.
• Continue enrollment in the Phase 2 proof-of-concept trial evaluating ALTO-203, with topline data expected in the first half of 2025.
• Continue enrollment in the Phase 2 proof-of-concept trial evaluating ALTO-101, with topline data expected in the second half of 2025.
• Advance additional product candidates through clinical development.
• Seek marketing authorizations for any product candidates that successfully complete clinical development.

Key Dates

Keywords

clinical trials, biopharmaceutical, neuroscience, psychiatry, biomarkers, ALTO-100, ALTO-300, ALTO-101, ALTO-203, MDD, bipolar depression, schizophrenia, regulatory approval, drug development, precision psychiatry